Robert Malone on vaccines: what the evidence says · JRE #1757
“The number that keeps getting cited is one in a thousand people have adverse events, including myocarditis. If myocarditis that requires hospitalization is one in 2,700.”
What the evidence says
Malone stated that myocarditis requiring hospitalization after mRNA COVID-19 vaccination occurs in about 1 in 2,700 recipients. CDC's VAERS-based surveillance, presented to the Advisory Committee on Immunization Practices in June 2021, found myocarditis reporting rates after a second mRNA dose of 62.8 per million in males aged 12-17 (about 1 in 15,900); a subsequent peer-reviewed CDC/FDA analysis published in JAMA (Oster et al., 2022) refined this to 70.7 per million second doses in males 12-15 and 105.9 per million in males 16-17 (roughly 1 in 9,400 to 1 in 14,100). That same JAMA analysis found about 96% of the reported myocarditis cases among people under 30 were hospitalized, mostly for monitoring, with 87% resolving symptoms by discharge, so the hospitalization-specific rate tracks closely with the overall myocarditis rate rather than being a separate, much smaller figure. Across the age and sex strata studied, no published surveillance estimate approaches a rate as high as 1 in 2,700; the best-supported figures for adolescent males are roughly three to five times rarer than the number cited. The claim therefore overstates the frequency of hospitalization-requiring vaccine-associated myocarditis relative to current CDC and peer-reviewed evidence.
- Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices, United States, June 2021 (MMWR) · government
- Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021 (JAMA, Oster et al., 2022) · government